MAF Test first mention in ESMO Clinical Guidelines for Bone health in cancer
Recently published: Bone Health in Cancer: ESMO Clinical Practice Guidelines (2020) for practice-changing precision medicine clinical routines devoted a section to discussed on Personalized Medicine.
"Validation of these results [re MAF biomarker] are awaited before this biomarker can be considered for routine use" (page 30). These guidelines were endorsed by the European Society for Medical Oncology (ESMO) and published in the Annals of Oncology journal in August 2020.
